Category: snoring and apnea

Nasal Stent Company Alaxo Names Sleep Specialist Its CMO 0

Nasal Stent Company Alaxo Names Sleep Specialist Its CMO

Alaxo Airway Stents has named board-certified otolaryngologist and sleep specialist Mark D’Agostino, MD, as its chief medical advisor, effective immediately.

“We are excited to welcome Dr D’Agostino as Alaxo’s new chief medical advisor,” says Terry Bayliss, CEO of Alaxo, in a release. As a founding member of the International Society of Sleep Surgeons and a member of the American Academy of Sleep Medicine Dr D’Agostino brings a wealth and knowledge and experience to Alaxo.”

D’Agostino says in a release, “I am looking forward to working with Alaxo as chief medical advisor. Nasal obstruction can cause or contribute to snoring, obstructive sleep apnea, headaches, halitosis, poor dental health, and have ill effects on metabolism. Alaxo provides a simple non-surgical cure for nasal obstruction. A clear nasal airway leads to improved mental and physical health, athletic performance and better sleep.”

D’Agostino is originally from North Haven, CT. Since 1995, he is board certified from the American Board of Otolaryngology and from the American Board of Sleep Medicine since 2010. He is a Fellow of the American Academy of Otolaryngology/Head and Neck Surgery …

Botox for TMJ May Not Lead to Bone Loss in Short Term, But More Research Is Needed 0

Botox for TMJ May Not Lead to Bone Loss in Short Term, But More Research Is Needed

Botox injections to manage jaw and facial pain do not result in clinically significant changes in jaw bone when used short term and in low doses, according to researchers at NYU College of Dentistry. However, they found evidence of bone loss when higher doses were used.

The researchers, whose findings are published in the Journal of Oral Rehabilitation, call for further clinical studies to track bone- and muscle-related changes with long-term use of Botox for TMJD, or temporomandibular muscle and joint disorders.

TMJDs are a group of common pain conditions that occur in the jaw joint and surrounding muscles, with the most common type involving the muscles responsible for chewing. While many individuals manage their TMJD symptoms with conservative treatments such as jaw exercises, oral appliances, dietary changes, and pain medication, some do not respond to these treatments.

Botox (or botulinum toxin), an FDA-approved injectable drug known for its wrinkle-reducing capabilities, is approved to treat certain muscle and pain disorders, including migraines. It works in part by temporarily paralyzing or weakening muscles. In the United States, a Phase 3 …

Can CTE Cause REM Sleep Behavior Disorder? 0

Can CTE Cause REM Sleep Behavior Disorder?

Repetitive head impacts are associated with development chronic traumatic encephalopathy (CTE). Some individuals diagnosed with CTE, a neurodegenerative disease, after death were reported to experience sleep dysfunction, but the type of disorder and its cause has never been formally explored.

A team led by researchers at the VA Boston Healthcare System and Boston University School of Medicine analyzed the brains of 247 athletes donated to the Veteran’s Affairs-Boston University-Concussion Legacy Foundation (VA-BU-CLF) Brain Bank to explore the relationship between contact sports participation, multiple brain diseases, and symptoms characteristic of rapid eye movement (REM) sleep behavior disorder (RBD). REM sleep behavior disorder occurs when the paralysis that normally occurs during REM sleep is incomplete or absent, causing individuals to “act out” their dreams by talking, flailing their arms and legs, punching, kicking, grabbing, and more.

[RELATED: REM Sleep Behavior Disorder Gets a Textbook]

While an estimated 1% of the general population suffers from REM sleep behavior disorder, scientists found that 32% of the contact sport athletes with CTE experienced sleep symptoms characteristic of REM sleep behavior disorder. The study’s results are …

Pulling Back the Curtain on AI in Sleep Medicine 0

Pulling Back the Curtain on AI in Sleep Medicine

Watch an ~90-minute free recording of a Sleep Review-produced webinar that discusses research and clinical applications surrounding artificial intelligence.

Sleep specialists and a physicist-data scientist discuss:

  • artificial intelligence (AI), sleep, and brain health;
  • opportunities and risks of AI in sleep medicine;
  • and how AI may impact sleep medicine moving forward.

[RELATED: How Machine Learning Could Transform the Way We Diagnose Narcolepsy]


The presenters are Nate Watson, MD, MSc; Jon Agustsson, PhD; and Emmanuel Mignot, MD, PhD.

Nate Watson, MD

Dr. Watson is Professor of Neurology, Co-director of the Sleep Center at the University of Washington, and Director of the Harborview Medical Center Sleep Clinic in Seattle, Washington. He is the former president of the American Academy of Sleep Medicine and the American Board of Sleep Medicine. Dr. Watson has held multiple research grants to study sleep disturbances and has published extensively for medical and lay audiences. His current investigations include the relationship between sleep-disordered breathing and cancer risk and the impact of artificial intelligence and consumer sleep technology on human sleep and sleep medicine.

Jon Agustsson, PhD

Dr. …

The Link Between Pregnancy and Sleep Apnea 0

The Link Between Pregnancy and Sleep Apnea

Higher levels of estrogen and progesterone can be a prime reason why pregnant women are susceptible to sleep apnea.

The increased levels of these hormones leads to fluid retention which can affect the upper airways as you lay down to sleep.

On top of this, the hormones also relax the muscles in the body, resulting in the narrowing of the upper airways — which in tandem with excess fluid creates the conditions for OSA.

The physiological changes of weight gain — and upward shift of the diaphragm — can predispose pregnant women to have sleep apnea, including the snoring which typically occurs with OSA.

The significant rise in estrogen levels also puts women at risk since estrogen induces various changes that lead to narrowing of the airways.

Get the full story at

from Sleep Review…

Intermittent Negative Pressure Therapy May Help Sleep Apnea Sufferers Feel More Rested 0

Intermittent Negative Pressure Therapy May Help Sleep Apnea Sufferers Feel More Rested

A study on intermittent negative pressure evaluated daytime sleepiness in a single-center, prospective, non-randomized clinical trial.

The study enrolled 7 men and 1 woman between the ages of 29 and 50 with moderate sleep apnea. They visited the Fukuoka Urasoe Clinic in Fukuoka, Japan, between September 2017 and March 2019. Researchers excluded patients with a history of cardiovascular diseases, cerebrovascular diseases, or diabetes mellitus.

Get the full story at

from Sleep Review…

Clinical Symptoms in Children vs Adults with Narcolepsy and Cataplexy 0

Clinical Symptoms in Children vs Adults with Narcolepsy and Cataplexy

The symptoms and sleep characteristics among patients with narcolepsy and cataplexy (NC) may differ according to the age at diagnosis.

Complications including obesity, night eating, parasomnia, sleep talking, and attention-deficit/hyperactivity disorder (ADHD) are more common in children, while sleep paralysis, obstructive sleep apnea, and reduced quality of life are more common in adults, according to study results published in CNS Neuroscience & Therapeutics.

Study researchers sought to assess the clinical symptoms and sleep measures in de novo patients diagnosed with NC before and after 18 years of age. The cohort for this retrospective study included 46 children (median age, 12 years; 61% boys) and 46 adults (median age, 28.5 years; 61% men). All study participants completed a standardized questionnaire and interview, as well as a sleep study.

Get the full story at

from Sleep Review…

12 Things to Know About a Home Sleep Testing Program 0

12 Things to Know About a Home Sleep Testing Program

From ease of use to immediate revenue to easy scoring and interpretation, a turnkey HST provider explains how to increase profits while providing high quality sleep apnea care, with little effort.

DreamClear is the turnkey home sleep apnea testing program that makes the entire process easy for providers and their patients.

Made by REMware, DreamClear home sleep testing provides:

  • Immediate revenue. Up to $5,000/month, based on test volume/reimbursement contracts.
  • Ease of use. You write the script and DreamClear handles the details.
  • Patients benefit from the most advanced HST program available.

Learn the 6 steps to DreamClear and the 12 facts you need to know about this turnkey HST program by downloading a free 2-page fact sheet now.


This content is paid for by:

Partner with Sleep Review on content marketing.

from Sleep Review…

Narcolepsy Drug Improves On-Road Vehicle Control 0

Narcolepsy Drug Improves On-Road Vehicle Control

Solriamfetol (Sunosi) significantly improved driving performance for patients with narcolepsy and daytime sleepiness due to obstructive sleep apnea, according to a pair of on-road driving studies sponsored by the drugmaker.

In the one-hour driving test, performed two hours after taking 300 mg solriamfetol or placebo, patients with narcolepsy showed less weaving with the active drug (difference in standard deviation of lateral positioning -1.9 cm, 95% CI -6.7 to 2.6, P=0.002), reported Frederick Vinckenbosch, MSc, of Maastricht University in the Netherlands.

Get the full story at

from Sleep Review…

Investigational Sleep Apnea Drug to Move to Phase 2 Trial 0

Investigational Sleep Apnea Drug to Move to Phase 2 Trial

Apnimed, a clinical-stage pharmaceutical company focused on developing medicines to treat sleep apnea and related disorders, reports the results of a Phase 1 study for a component of the company’s lead combination drug candidate, AD109, which is being explored as a pharmacologic treatment for obstructive sleep apnea (OSA). In this healthy volunteer study, R-oxybutynin, a key component of AD109, demonstrated a favorable pharmacokinetic (PK) profile and was well tolerated with no adverse events related to the study drug.

“Obstructive sleep apnea represents a significant public health problem in the US and around the globe and current treatment options do not meet the needs of patients,” says Larry Miller, MD, Apnimed CEO, in a release. “We believe that AD109, an oral drug candidate dosed once-daily at bedtime, could be a significant breakthrough for these patients by giving them a simple, safe, and effective solution that does not require a CPAP device or surgery. The results from this study support our advancement of this program.

“We look forward to initiating a Phase 2 study with AD109 in Q4 of this year.”